Oculis Holding AG (OCS) Net Cash Flow (2022 - 2026)

Oculis Holding AG's (OCS) quarterly Net Cash Flow came in at $10.6 million in Q1 2026, down 88.82% year-on-year from $94.4 million in Q1 2025, and down 87.5% quarter-over-quarter from $84.5 million in Q4 2025.

Oculis Holding AG (OCS) Net Cash Flow (2022 - 2026) Analysis & Trends

Oculis Holding AG's Net Cash Flow history runs 5 years deep, the most recent figure standing at $10.6 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow fell 88.82% year-over-year to $10.6 million in Q1 2026; TTM through Mar 2026 was $56.0 million, a 40.7% decrease from a year earlier, with the FY2025 full-year figure at $72.0 million, up 674.33% from the prior year.
  • Net Cash Flow declined to $10.6 million in Q1 2026 per OCS's latest filing, from $84.5 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $94.4 million in Q1 2025 and bottomed at -$20.1 million in Q2 2025.
  • The 5-year median for Net Cash Flow is -$5.7 million (2022), against an average of $14.7 million.
  • Across the five-year window, Net Cash Flow plunged 205.76% in 2023 and jumped 1030.89% in 2025, its largest moves.
  • Year by year, Net Cash Flow stood at -$8.6 million in 2022, then soared by 219.38% to $10.3 million in 2023, then plunged by 187.95% to -$9.1 million in 2024, then jumped by 1030.89% to $84.5 million in 2025, then sank by 87.5% to $10.6 million in 2026.
  • Per Business Quant, the three latest OCS Net Cash Flow figures stand at $10.6 million (Q1 2026), $84.5 million (Q4 2025), and -$18.9 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 10.56 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 224.46 Mn
4 NuCana 279.75 Bn 279.75 Bn - -1.34 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 457.40 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -152.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 57.19 Mn
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn 60.68 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 10.56 Mn
Mar 31, 2026 10.56 Mn
Dec 31, 2025 84.47 Mn
Dec 31, 2025 84.47 Mn
Sep 30, 2025 -18.91 Mn
Sep 30, 2025 -18.91 Mn
Jun 30, 2025 -20.10 Mn
Jun 30, 2025 -20.10 Mn
Mar 31, 2025 94.39 Mn
Mar 31, 2025 94.39 Mn
Dec 31, 2024 -9.07 Mn
Dec 31, 2024 -9.07 Mn
Sep 30, 2024 -13.33 Mn
Sep 30, 2024 -13.33 Mn
Jun 30, 2024 22.47 Mn
Jun 30, 2024 22.47 Mn
Mar 31, 2024 -17.87 Mn
Mar 31, 2024 -17.87 Mn
Dec 31, 2023 10.32 Mn
Dec 31, 2023 10.32 Mn